Collegium Pharmaceutical Garners $50,000,000 New Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=42e4c741-c8c6-4b4d-8049-ce5f38b61a43 - Date
3/11/2015 - Company Name
Collegium Pharmaceutical - Mailing Address
780 Dedham Street Canton, MA 02021 USA - Company Description
Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. - Website
http://www.collegiumpharma.com - Transaction Type
Venture Equity - Transaction Amount
$50,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER (oxycodone extended-release capsules), through potential FDA approval and commercial launch as well as to fund operational growth and other pipeline development programs. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
